8-K: OpGen Faces Delisting Threat After Nasdaq Notifies Company of Additional Non-Compliance

OpGen, Inc. received a notice from Nasdaq regarding its failure to file its quarterly report, adding to existing non-compliance issues and increasing the risk of delisting.

Summary

• OpGen, Inc. has received a notice from Nasdaq stating that the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2024.
• This non-compliance is an additional basis for potential delisting, on top of previous notices related to the minimum bid price rule and the late filing of the annual report.
• The company has submitted a response to the Nasdaq Hearings Panel and plans to file the Form 10-Q as soon as practicable, but there is no guarantee of the filing date or the final decision of the panel regarding delisting.
• The company was previously granted an extension until June 3, 2024, to regain compliance with the minimum bid price rule and the annual report filing, and the panel will consider the new delinquency in this context.
• The notice has no immediate effect on the listing of the company's securities on The Nasdaq Capital Market.

Sentiment

Score: 2

Explanation: The document indicates significant negative developments for the company, including multiple non-compliance issues and a high risk of delisting, which is very concerning for investors.

Positives

• The company is working diligently to finalize the Form 10-Q and plans to file it as soon as practicable.
• The notice has no immediate effect on the listing or trading of the company's common stock on Nasdaq.

Negatives

• OpGen is facing potential delisting from Nasdaq due to multiple non-compliance issues.
• The company has failed to maintain a minimum bid price of $1.00 per share for a 30 consecutive business day period.
• The company has not filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
• The company has not filed its Quarterly Report on Form 10-Q for the period ended March 31, 2024.

Risks

• There is a risk that the company will not regain compliance with Nasdaq's listing rules.
• The Nasdaq Hearings Panel may decide to delist the company's securities.
• The company's ability to continue to finance its business and operations is at risk.
• The company's liquidity and working capital requirements are a concern.

Future Outlook

The company plans to file its Form 10-Q as soon as practicable and is requesting additional time to regain compliance with Nasdaq listing rules, but there is no assurance of success.

Management Comments

• The Company plans to file its Form 10-Q as soon as practicable.
• The Company has been in communication with Nasdaq to request that the Nasdaq Hearings Panel continue to permit the Company until June 3, 2024 to regain compliance with the Minimum Bid Price Rule and file the Company's Form 10-K and for additional time to regain compliance with the Periodic Filing Rule.

Industry Context

This announcement highlights the challenges faced by smaller companies in maintaining compliance with listing requirements, particularly in the biotech sector where financial performance can be volatile.

Comparison to Industry Standards

• Many biotech companies face challenges in maintaining Nasdaq listing compliance, especially those with volatile stock prices or delays in financial reporting.
• Companies like OpGen, which are in the early stages of commercialization, often struggle to meet the financial metrics required for continued listing.
• The failure to file financial reports on time is a serious issue that can lead to delisting, and this is not unique to OpGen, but it is a significant concern for investors.

Stakeholder Impact

• Shareholders face the risk of significant losses if the company is delisted.
• Employees may be concerned about the company's future and job security.
• Customers and suppliers may be concerned about the company's ability to continue operations.

Next Steps

• The company plans to file its Form 10-Q as soon as practicable.
• The company is requesting additional time to regain compliance with Nasdaq listing rules.
• The Nasdaq Hearings Panel will consider the delinquent Form 10-Q in connection with its prior grant of an extension.

Key Dates

Keywords

delisting, Nasdaq, non-compliance, minimum bid price, Form 10-Q, Form 10-K, financial reporting, securities, compliance